13 th ILCC Huntington Beach July 20 th, 2012 Paul Baas NKI-AVL
|
|
- Felix Quinn
- 5 years ago
- Views:
Transcription
1 13 th ILCC Huntington Beach July 20 th, 2012 Paul Baas NKI-AVL
2 Advisor: Merck Sharp Dohme Pfizer Research funding: Pfizer Roche
3 The effect of the Greece situation
4 Multistep carcinogenesis in MPM Mutsaers, 2004 Durable, fire and heat resistant fibrous mineral To strengthen materials or serve as insulation Accumulation of asbestos fibers and chronic tissue injury Persistent stimulation of tissue repair Loss of contact-dependent growth inhibition and tumor progression
5 Epidemiology and tumorigenesis Incidence: Europe will peak between 2015 and 2020 US is at its peak Developing worlds are at very high risk Latency period from first exposure: years Genetic susceptibility: frequent inactivation of tumor suppressor genes include p16 INK4A /p14 ARF and neurofibromatosis type 2 (NF2) BAP1 (3p21.1) mutation involves ubiquitination of histones; germline mutations predispose to MPM J Testa 2011, Nature Genetics; Bott Nature Genetics 2011
6 Cumulative incidence of MPM and asbestos use Park, 2011
7 Mesothelioom wereldwijd Mesothelioma Incidence Worldwide ( ) ( )
8 Cell Type Epitheliod Mixed (Biphasic) Sarcomatous Pleiomorphic Tubulopapillary Epitheliod Glandular Large Cell (giant cell) Small Cell Adenoid cystic Signet ring MSKCC, Semin Thorac Cardiovasc Surg 2009; Courtesy, W. Travis
9 Diagnosis Cytology vs Histology Thoracentesis confirmatory in 35-40% Abrams Needle biopsy confirmatory in 40-50% Thoracoscopy 94-98% 1-2 x 5mm ports-no FROZEN SECTION DIAGNOSIS Cancer :389-93, Chest :1549, Chest :1362
10 Differentiation from Lung Cancer Histology Meso Adeno PAS stain Neg Pos Mucicarmine Neg Pos Immunostaining CEA Neg Pos TTF-1 Neg Pos LeuM-1 (CD 15) Neg Pos Vimentin Pos Neg Cytokeratin 5/6 Pos Neg Calretinin Pos Neg EMA Pos Neg WT1 Pos Neg HBMB1 Pos Neg Mesothelin Pos Neg D2-40 Pos Neg B72.3 Neg Pos MOC-31 Neg Pos Ber-Ep4 Neg Pos BG8 Neg Pos Epithelioid MPM Calretinin Arch Pathol Lab Med :1317, Eur Respir J :479
11 Biomarkers Blood, Serum, Effusion Mesothelin (SMRP) Osteopontin CYFRA 21-1 CA 125 PDGF MPF Tissue CDKN2A MMP2 VEGF Bax EGFR COX-2 P53 PTEN ERCC 1 TS CEA in serum must be normal!!!! NEJM :1564, Ann Thorac Surg :265, Mol Diagn Ther : 375, Eur J CT Surg :502, JCO :1534
12 Staging Systems IMIG 2003 (update 2013?) AJJC (update 2010)
13 Stage IA T1a N0M0 Stage IB T1b N0 M0 Stage II T2 N0 M0 Stage III T1, T2 N1 M0 T1, T2, N2, M0 T3, N0, N1, N2, M0 Stage IV T4 Any N M0 Any T N3 M0 Any T Any N, M1 J Thorac Cardiovas Surg : 620
14 PET Utility in the Evaluation MPM Disease extent-pleura of involved, total volume of disease and metastatic involvement, node assessment Combined with CT and Mediastinoscopy, PET-CT identifies 29% of patients who are potential inoperable T4 and M1, NPV 75%, PPV 50% Caution: not reliable after (talc) pleurodesis NEJM :1591, Eur J Cardiothor Thorac S :1090
15 FDG-PET: Prognostication Patient A-SUV max 9.6 & TGV 240 Patient B-SUV max 9.4 & TGV 2,523 Total Glycolytic Volume correlation with survival?? Semin Thorac Cardiovasc Surg : 111 Clin Cancer Res 2010;16:2409
16 Systemic Therapy Chemotherapy provides symptom relief and increased OS Based on a landmark study of Vogelzang and Meerbeeck: the combination of cisplatin and anti-folte is standard Multimodality studies use neoadjuvant chemotherapy followed by extrapleural pneumonectomy or pleurectomy/decotication with or without RT Optimal second line chemotherapy is not defined Novel and targeting agents: so far no or very limited success
17 Phase III first line MS01 study (UK) based study MST p Randomized Phase 3, 3-arm study (incomplete) MVP (mitomycin-vinblastine-cisplatin) 8.5 ns Vinorelbine ASC = active symptom control 7.6 Vogelzang study (US) Cisplatin 9.3 <0.001 Cisplatin/pemetrexed 12.3 Van Meerbeeck (EORTC) Cisplatin Cisplatin/raltitrexed 11.2 Muers MF Lancet. 2008;371(9625):
18 How to improve on platinum- pemetrexed? Do we need platinum-based combo s? Variations in scheduling Dose escalation Maintenance pemetrexed Better cytostatic drugs Other antifolates Vinca alkaloids Anthracyclins: amrubicin New platins Epothilones Better patient selection In vitro drug resistance Critical mutation (MTAPdeletion) Predictive biomarkers: TS, ERCC1 Targeted agents Anti-mesothelin immunotoxin Bevacizumab HDAC-inhibitor Thalidomide PI3Kinase inhibitor
19 Do we need platinum-based combos? IPD N=1056 OS Logrank (p value) PLATINUM 9.4 <0.001 NON-PLATINUM 8.2 IPD N=1056 OS Logrank (p value) Combination 9.5 <0.001 Single agent 8.1 Fennell, in press
20 Second line chemotherapy Irinotecan/cisplatin/mitomycin C: RR 10% Fennell, Cancer 2007 Pemetrexed vs BSC: RR 18%, better disease control rate (59% vs 19%), no survival benefit Jassem, JCO 2008 Vinorelbine and gemcitabine: 30 pts, RR10%, median OS 10.6 months Zucali, Cancer, 2008 Vinorelbine: 63 pts, RR 16%, median OS 9.6 months Stebbing, Lung Cancer 2009
21 (Switch) Maintenance Therapy
22 CT thorax Toxicity randomization Observation >4 cycles 2-9 weeks weeks chemotherapy recovery 100mg 200mg Thalidomide start Stop PD Thalidomide vs observation in non progressing patients after CT Primary Objective: 50% increase in TTP 222 patients randomized
23 Probability TTP and OS TTP OS No further treatment No Thalidomide further treatment until progression Thalidomide until progression HR = 1.0 ( ), p=0.71 HR 1.2 ( ), p= Time (weeks) Time (mths)
24 Maintenance studies Thalidomide vs. obs Phase III negative Bevacizumab vs. obs Phase III ongoing Cetuximab vs. obs Phase II ongoing Pemetrexed vs. obs Phase III planned
25 Biologicals
26 Summary of Biological Agents Gefitinib (Govindan, CCR 2005) Erlotinib (Garland, JCO 2007) Imatinib (Mathi, LC 2005) Sunitinib (Nowak pers comm) Sunitinib (Laurie, JTO 2011) Bortezomib (O Brien 2012) Thalidomide (Baas ASCO 2011) Vorinostat (Krug, ESMO 2011) Bevacizumab (Kindler JCO 2012) Axitinib (Buikhuisen) negative negative negative positive? negative negative negative negative negative in preparation
27 Operative Procedures Diagnostic pleural Bx, VATS Palliative for effusion control talc pleurodesis VATS/open parietal pleurectomy VATS/open Curative Intent Pleurectomy / Decortication (P/D) Extrapleural Pneumonectomy (EPP)
28 Comparison of EPP vs P/D 3 Institutions MSKCC, Karmanos, NYU , 663 Consecutive Patients, Retrospective Mortality EPP 7% P/D 3% Poor Prognosis for Adv Stage, NonEpitheliod Histology, EPP, Surgery alone, Male Gender EPP HR 1.4 (p<.001) controlling for stage, histology, gender and multimodal Rx J Thor Cardiovas Surg : 620
29 Multimodality therapy Goal: Intervention: 1. curative therapy 2. prolonged survival balanced with quality of life - radical resection/maximal cyto-reduction - systemic treatment - +/- radiotherapy
30 Message from MARS Courtecy Tom Treasure January 2011
31 Neoadjuvant chemotherapy, EPP and radiotherapy in MPM MARS: 16/24 randomized to EPP had intended treatment: med survival 14.4 months 3/26 randomized to no EPP eventually had EPP: med survival 19.5 months Operative mortality 18%
32 Dilemmas The role and type of surgery in MPM continues to be a matter of debate no large randomized studies avalable non-controlled case series - different staging systems - different patients selection/histology - different combinations of other treatments - different experience of a specialized surgical team
33 Conclusions (1) Role of EPP dubious, if any Small number of patients benefit Focus now on pleurectomy/decortication Never R0 resection: odds against better outcome Beware of surgical triumphalism Randomised trials needed
34 Conclusions (2) First line chemotherapy Requires a platinum-antifolate backbone Likely equipoise between different combo s Tumors recur within 2 years Second Line Chemotherapy No standard yet Future lies in better patient selection By a predictive baseline biomarker By use of molecular targeted drugs (combinations?) Both adequately studied, preferably via randomized phase 2 studies in 1st line with PFS-(R) as primary endpoint
35 Latest news from Europe
Systemic Management of Malignant Pleural Mesothelioma
ESO-ESMO EASTERN EUROPE AND BALKAN REGION MASTERCLASS IN MEDICAL ONCOLOGY 15.June-19.June 2018 Belgrade, Serbia Systemic Management of Malignant Pleural Mesothelioma Dragana Jovanovic University Hospital
More informationMalignant pleural Mesothelioma: A Year In Review
Malignant pleural Mesothelioma: A Year In Review Rabab Gaafar,MD Prof. Medical Oncology NCI Cairo University National Cancer Institute Conference 2015 ASCO news in Mesothelioma Introduction ASCO news second
More informationThe surgeon: new surgical aproaches
The surgeon: new surgical aproaches Paul Van Schil, MD Department of Thoracic and Vascular Surgery Antwerp University, Belgium no disclosures, no conflict of interest Malignant pleural mesothelioma: clinical,
More informationMalignant Pleural Mesothelioma COMBINED TREATMENT
Malignant Pleural Mesothelioma COMBINED TREATMENT Federica Grosso incidence Italy
More informationTreatment of malignant pleural mesothelioma: current status and future directions
Review: Clinical Trial Outcomes Treatment of malignant pleural mesothelioma: current status and future directions Clin. Invest. (2011) 1(7), 999 1018 Malignant pleural mesothelioma (MPM) is an aggressive
More informationRecent Advances in the Management of Malignant Pleural Mesothelioma
Lucerne, 1.7.06 Recent Advances in the Management of Malignant Pleural Mesothelioma Rolf Stahel, MD University Hospital Zurich, Switzerland Pleural plaques Pleural plaques Asbestosis Pleural mesothelioma
More informationSystemic therapy in early stage NSCLC. Disclosures
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
More informationChemotherapy Induced Pathologic Complete Response in Malignant Pleural Mesothelioma. A Review and Case Report
STATE OF THE ART: CONCISE REVIEW Chemotherapy Induced Pathologic Complete Response in Malignant Pleural Mesothelioma A Review and Case Report Cecilia Bech, MD, and Jens Benn Sørensen, MD, DMSc, MPA Introduction:
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationWell-differentiated Papillary Mesothelioma of the Pleura Diagnosed by Video-Assisted Thoracic Surgical Pleural Biopsy : A Case Report
Showa Univ J Med Sci 25 1, 67 72, March 2013 Case Report Well-differentiated Papillary Mesothelioma of the Pleura Diagnosed by Video-Assisted Thoracic Surgical Pleural Biopsy : A Case Report Yuri TOMITA
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationTherapeutic Surgery for Nonepithelioid Malignant Pleural Mesothelioma: Is it Really Worthwhile?
Therapeutic Surgery for Nonepithelioid Malignant Pleural Mesothelioma: Is it Really Worthwhile? Bram Balduyck, MD, Delphine Trousse, MD, Apostolos Nakas, MD, Antonio E. Martin-Ucar, MD, John Edwards, MD,
More informationGiorgio V. Scagliotti IASLC President University of Torino Department of Oncology
Giorgio V. Scagliotti IASLC President University of Torino Department of Oncology giorgio.scagliotti@unito.it Rare disease ( 3 cases/100.000), however.. In Italy more than 1.500 new cases/year Almost 40-50%
More informationACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016
Diagnosing Mesothelioma in Limited Tissue Samples Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016 Sanja Dacic, MD, PhD University of Pittsburgh ACCME/Disclosures GENERAL RULES
More informationOriginal Article. Keywords: Mesothelioma; surgery; platelet
Original Article Clinical role of a new prognostic score using platelet-tolymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy Tetsuzo Tagawa 1,2, Masaki
More informationMesothelioma: diagnostic challenges from a pathological perspective. Naseema Vorajee August 2016
Mesothelioma: diagnostic challenges from a pathological perspective Naseema Vorajee August 2016 Naseema.vorajee@nhls.ac.za Pleural diseases (whether neoplastic, reactive or infective) may have similar
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationSCLC: Developments in systemic treatment
SCLC: Developments in systemic treatment Egbert F. Smit, Dept. Pulmonary Diseases, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands Staging Outline First line treatment Second line treatment
More informationMALIGNANT PLEURAL MESOTHELIOMA: SPOTLIGHT ON RECENT ADVANCES IN DIAGNOSIS AND TREATMENT
MALIGNANT PLEURAL MESOTHELIOMA: SPOTLIGHT ON RECENT ADVANCES IN DIAGNOSIS AND TREATMENT Aline N. Zouk, *Hitesh Batra Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationA Retrospective Study of Chemotherapy with and without Pemetrexed in Malignant Pleural Mesothelioma
A Retrospective Study of Chemotherapy with and without Pemetrexed in Malignant Pleural Mesothelioma MASAYOSHI HIGASHIGUCHI, HIDEKAZU SUZUKI, TOMONORI HIRASHIMA, MASASHI KOBAYASHI, SHO GOYA, NORIO OKAMOTO,
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationTreatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline TABLE OF CONTENTS Data Supplement 1: Evidence Tables Data Supplement 2: Search Strategy String
More informationExtrapleural Pneumonectomy: A Blessing or a Curse in the Management of Pleural Malignant Mesothelioma?
Original Research Extrapleural Pneumonectomy: A Blessing or a Curse in the Management of Pleural Malignant Mesothelioma? PLEURA January-December 2015: 1-7 ª The Author(s) 2015 DOI: 10.1177/2373997515595219
More informationThoracic malignancies other than NSCLC
1 Thoracic malignancies other than NSCLC Rolf Stahel University Hospital of Zürich Amsterdam, 26.5.2017 2 Emerging new approaches to SCLC Bunn, JTO 2016 3 DDL3 DLL 3 localized in Golgi apparatus DLL 3
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationThe Imaging Journey of Patients with Malignant Pleural Mesothelioma: Experience of a Tertiary Mesothelioma MDT
The Imaging Journey of Patients with Malignant Pleural Mesothelioma: Experience of a Tertiary Mesothelioma MDT V. Lam, J. Brozik, A. J. Sharkey, A. Bajaj, D. T. Barnes Glenfield Hospital, Leicester, United
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationEstado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationBrain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland
Brain metastases and meningitis carcinomatosa: a palliative situation? Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland SAMO, Lucerne, February 1-2, 2013 Treatment options for NSCLC patients
More informationChemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future
Perspective Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future Anna K Nowak 1,2,3 1 Department of Medical Oncology, Sir Charles Gairdner Hospital,
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Mesothelioma: Live to Fight Another Day Andrea S. Wolf, MD, Raja M. Flores, MD PII: S0022-5223(17)32747-2 DOI: 10.1016/j.jtcvs.2017.11.060 Reference: YMTC 12301 To appear in: The Journal
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationMalignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient
Editorial Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient Ori Wald, David J. Sugarbaker Division of General Thoracic Surgery, Michael E. DeBakey
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationLung Cancer. Second line therapy in malignant pleural mesothelioma: A systematic review
Lung Cancer 89 (2015) 223 231 Contents lists available at ScienceDirect Lung Cancer journal homepage: www.elsevier.com/locate/lungcan Review Second line therapy in malignant pleural mesothelioma: A systematic
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationTreatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward
Treatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward Maha Hussain, MD, FACP Professor of Medicine & Urology Co-Leader Prostate/GU Oncology Program Associate Director for Clinical
More informationMalignant Mesothelioma
Recent Results in Cancer Research 189 Malignant Mesothelioma Bearbeitet von Andrea Tannapfel 1. Auflage 2011. Buch. xii, 196 S. Hardcover ISBN 978 3 642 10861 7 Format (B x L): 16 x 24 cm Gewicht: 574
More informationChemotherapy treatment in malignant pleural mesothelioma: a difficult history
Review Article Chemotherapy treatment in malignant pleural mesothelioma: a difficult history Marika Cinausero 1,2,3, Karim Rihawi 3, Francesca Sperandi 3, Barbara Melotti 3, Andrea Ardizzoni 3 1 Department
More informationMesothelioma Pathobasic. Lukas Bubendorf Pathology
Mesothelioma Pathobasic Lukas Bubendorf Pathology Mechanisms of Asbestos Carcinogenesis in Mesothelioma Asprin High-mobility group protein B1 master switch HMGB1 Initiation/ perpetuation of inflamm. response
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationArkadiusz Dudek, MD, PhD, FACP
CALGB 30901 Randomized Phase II Study of Maintenance Pemetrexed vs. ObservaEon for PaEents with Malignant Mesothelioma without Progression aier First- Line Chemotherapy Study Chair: Arkadiusz Dudek, MD,
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationLung Cancer 83 (2014) Contents lists available at ScienceDirect. Lung Cancer. journal homepage:
Lung Cancer 83 (2014) 78 82 Contents lists available at ScienceDirect Lung Cancer journal homepage: www.elsevier.com/locate/lungcan Radical pleurectomy/decortication followed by high dose of radiation
More informationThe Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer
The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer Nathan A. Pennell, M.D., Ph.D. Assistant Professor Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute www.cancergrace.org
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationExtended pleurectomy decortication for malignant pleural mesothelioma in the elderly: the need for an inclusive yet selective approach
Interactive CardioVascular and Thoracic Surgery 25 (2017) 696 702 doi:10.1093/icvts/ivx221 Advance Access publication 21 July 2017 ORIGINAL ARTICLE Cite this article as: Sharkey AJ, Bilancia R, Tenconi
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationManagement of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
More informationUnderstanding Pleural Mesothelioma
Understanding Pleural Mesothelioma UHN Information for patients and families Read this booklet to learn about: What is pleural mesothelioma? What causes it? What are the symptoms? What tests are done to
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Mesothelioma
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma [Based on WOSCAN SCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED WHEN PRINTED Document
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationMalignant pleural mesothelioma (MPM) has a poor prognosis,
ORIGINAL ARTICLE Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia Arman Hasani, MBBS, FRACP,* John M. Alvarez, MBBS, FRACS, Jenny Ma Wyatt,
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES LUNG SITE MESOTHELIOMA Lung Site Group Mesothelioma Authors: Dr. Meredith Giuliani, Dr. Andrea Bezjak 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More informationClinicopathological Study on Malignant Pleural Mesotheliomas
Table of Contents Clinicopathological Study on Malignant Pleural Mesotheliomas PL-4-03 Kenzo Hiroshima Kenzo Hiroshima 1, Akira Iyota 1, Kiyoshi Sibuya 1, Toshikazu Yusa 2, Takehiko Fujisawa 1 and Yukio
More informationGuidelines of the European Respiratory Society and the European Society. of Thoracic Surgeons for management of Malignant Pleural Mesothelioma
ERJ Express. Published on August 28, 2009 as doi: 10.1183/09031936.00063109 Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for management of Malignant Pleural
More informationTreatment of malignant pleural mesothelioma (MPM)
Original Article A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma A Review of 12 Years Experience Isabelle Opitz, MD,* Martina Friess,
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationPLEURAL MESOTHELIOMA
PLEURAL MESOTHELIOMA B A C K G R O U N D E R 1. Overview 2. What is pleural mesothelioma? 3. What are the risk factors for pleural mesothelioma? 4. What are the clinical features of pleural mesothelioma?
More informationAdjuvant Therapy in NSCLC. Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia
Adjuvant Therapy in NSCLC Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia Agenda What do we expect today from new adjuvant chemotherapy Which data do we have with targeted agents
More informationPrognostic and predictive biomarkers in
OLOGICAL SCIENCES O DEPT. OF CLINICAL & BIO UNIVERSITY UNIVERSTY OF TORINO Prognostic and predictive biomarkers in early stage NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical &
More informationLung cancer update 2007
Lung cancer update 2007 HARMESH R NAIK, MD. January 24, 2007 Epidemiology (world) Estimated 1.35 million new cases in world in 2002 Estimated 1.179 million deaths in world in 2002 Common cancer diagnosis
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationPersonalized Medicine for Advanced NSCLC in East Asia
Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationMalignant mesothelioma
Published Online January 4, 2010 Malignant mesothelioma R. M. Rudd * London Lung Cancer Group, 54 New Cavendish Street, London W1G 8TQ, UK Introduction: Mesothelioma is a malignant tumour of the pleura
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationThe Evolving Role of Adjuvant Therapies
Therapy-predictive markers for adjuvant chemotherapy The Evolving Role of Adjuvant Therapies Micrometastasis Prognostic Markers (BRCA1) Cured No Further Tx Chemosensitive Rafael Rosell th European Perspectives
More informationHOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
More informationMalignant pleural mesothelioma: The standard of care and challenges for future management
Critical Reviews in Oncology/Hematology 78 (2011) 92 111 Malignant pleural mesothelioma: The standard of care and challenges for future management Jan P. van Meerbeeck a,, Arnaud Scherpereel b, Veerle
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationFollow up of the Guidelines for Cytopathologic Diagnosis of Malignant Mesothelioma
Follow up of the Guidelines for Cytopathologic Diagnosis of Malignant Mesothelioma Assoc. Prof. Katalin Dobra, Senior Lecturer in Molecular Pathology Karolinska University Hospital Stockholm, Sweden Disclosure
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationAccepted Manuscript. Surgery for mesothelioma: less is more, more or less. Steven Milman, MD, Thomas Ng, MD
Accepted Manuscript Surgery for mesothelioma: less is more, more or less Steven Milman, MD, Thomas Ng, MD PII: S0022-5223(17)32706-X DOI: 10.1016/j.jtcvs.2017.11.029 Reference: YMTC 12266 To appear in:
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More information11/21/ M with LUL Mass Case Presentation / Round Table Discussion. Multiple-choice question What stage is this tumor?
MS 62M with LUL Mass Case Presentation / Round Table Discussion Dr. Jasleen Kukreja and Johannes Kratz Department of Thoracic Surgery University of California, San Francisco 62M, presented to clinic 6/2009
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More informationThe role of surgical resection in the management of malignant
ORIGINAL ARTICLE Frequency of Use and Predictors of Cancer-Directed Surgery in the Management of Malignant Pleural Mesothelioma in a Community-Based (Surveillance, Epidemiology, and End Results [SEER])
More information